Antithrombotic and antiplatelet activity of an organometallic rhodium(I) complex incorporating a substituted thieno‐[2,3‐d]‐pyrimidine ligand: Synthesis, structural characterization, and molecular docking calculations
- 15 February 2021
- journal article
- research article
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 35 (6) , e6210
Abstract
The antiplatelet and antithrombotic activity of a novel organometallic rhodium(I) complex of the formula [Rh(cod)Cl(tpc)] (1) (cod = cis‐1,5‐cyclooctadiene; tpc = methyl 2‐amino‐4‐(diethylamino)‐thieno‐[2,3‐d]‐pyrimidine‐6‐carboxylate) was investigated. Complex 1 was easily synthesized by a one‐pot, high‐yield reaction and was fully characterized by standard spectroscopic techniques including FT‐IR, UV–Vis, and NMR spectroscopy and by elemental analysis. The molecular structures of tpc and 1 were determined by single‐crystal X‐ray crystallography. Complex 1 displayed a slightly distorted square planar geometry and is the first crystallographically characterized example of a coordination compound bearing the ligand precursor tpc. Biological studies demonstrate that 1 displays strong antiplatelet and antithrombotic properties in vitro, by inhibiting both the aggregation of human and washed rabbit platelets induced by the potent inflammatory and thrombotic mediator, platelet‐activating factor (PAF) in the micromolar range. This is an approach of continuous interest in the field. Molecular docking calculations suggest that 1 can fit at the ligand‐binding site of the PAF receptor (PAFR) and thus block PAF thrombotic activities, through an antagonistic effect on the PAF/PAFR‐related pathway, which is in accord with the experimental findings. Complex 1 constitutes an interesting example of a metal‐based PAF inhibitor with promising antiplatelet, antithrombotic, and anti‐inflammatory activity, because PAF is the most potent inflammatory lipid mediator. This is also supported by the fact that 1 is an inhibitor of other inflammatory and thrombotic mediators like thrombin, along with well‐established platelet agonists like ADP and collagen.Keywords
Funding Information
- National and Kapodistrian University of Athens (16672)
This publication has 59 references indexed in Scilit:
- Rhodium(III) and iridium(III) complexes as anticancer agentsInorganica Chimica Acta, 2012
- H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulationsNucleic Acids Research, 2012
- In vitro anti-inflammatory and anti-coagulant effects of antibiotics towards Platelet Activating Factor and thrombinJournal of Inflammation, 2011
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Synthetic and spectroscopic characterization of Rh(I)-( S )-amino acid complexes with diphosphine and triphosphine ligandsJournal of Coordination Chemistry, 2007
- Non Platinum Metal Complexes as Anti‐cancer DrugsArchiv der Pharmazie, 2007
- A critical account on π–π stacking in metal complexes with aromatic nitrogen-containing ligands †J. Chem. Soc., Dalton Trans., 2000
- Synthesis of thieno[2,3‐d]pyrimidines from 4,6‐dichloropyrimidine‐5‐carbaldehydesJournal of Heterocyclic Chemistry, 1993
- The C-H.cntdot..cntdot..cntdot.O hydrogen bond in crystals: what is it?Accounts of Chemical Research, 1991
- Di‐μ‐Chloro‐Bis(η 4 ‐1,5‐Cyclooctadiene)‐Dirhodium(I)1990